Concepedia

Publication | Open Access

Potential Risk Factors for Nivolumab-induced Thyroid Dysfunction

DOIFull Paper Access

29

Citations

7

References

2017

Year

Haruhiko Yamazaki, Hiroyuki Iwasaki, Toshinari Yamashita, Nobuyasu Suganuma, Takashi Yamanaka, Katsuhiko Masudo, Hirotaka Nakayama, Kaori Kohagura, Yasushi Rino, Munetaka Masuda
In Vivo

Abstract

The total number of doses administered may be a risk factor for the development of thyroid dysfunction after nivolumab therapy.

References

YearCitations

Page 1